Evidence map›Paper›PMID 26489516›Full record

ArticleScientific reports2015

Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury.

A D B Vliegenthart, J M Shaffer, J I Clarke, L E J Peeters, A Caporali, D N Bateman, D M Wood, P I Dargan, D G Craig, J K Moore and 10 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 2 pooled it
22.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. IsomiR stoichiometry changes as disease biomarkers.Molecular therapy. Nucleic acids · 2025
    Article
  7. Review
  8. Article
  9. Food science & nutrition · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 3 countries.

A D B VliegenthartPharmacology, Toxicology and Therapeutics, University/BHF Centre for Cardiovascular Science, Edinburgh University, UK.
J M ShafferQiagen, Fredrick, Maryland, USA.
J I ClarkeMRC Centre for Drug Safety Science, Department of Molecular &Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
L E J PeetersPharmacology, Toxicology and Therapeutics, University/BHF Centre for Cardiovascular Science, Edinburgh University, UK.
A CaporaliPharmacology, Toxicology and Therapeutics, University/BHF Centre for Cardiovascular Science, Edinburgh University, UK.
D N BatemanPharmacology, Toxicology and Therapeutics, University/BHF Centre for Cardiovascular Science, Edinburgh University, UK.
D M WoodClinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
P I DarganClinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
D G CraigScottish Liver Transplantation Unit, Royal Infirmary of Edinburgh, Edinburgh, UK.
J K MooreScottish Liver Transplantation Unit, Royal Infirmary of Edinburgh, Edinburgh, UK.
A I ThompsonMRC Centre for Inflammation Research, University of Edinburgh, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh.
N C HendersonMRC Centre for Inflammation Research, University of Edinburgh, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh.
D J WebbPharmacology, Toxicology and Therapeutics, University/BHF Centre for Cardiovascular Science, Edinburgh University, UK.
J SharkeyMRC Centre for Drug Safety Science, Department of Molecular &Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
D J AntoineMRC Centre for Drug Safety Science, Department of Molecular &Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
B K ParkMRC Centre for Drug Safety Science, Department of Molecular &Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
M A BaileyPharmacology, Toxicology and Therapeutics, University/BHF Centre for Cardiovascular Science, Edinburgh University, UK.
E LaderQiagen, Fredrick, Maryland, USA.
K J SimpsonScottish Liver Transplantation Unit, Royal Infirmary of Edinburgh, Edinburgh, UK.
J W DearPharmacology, Toxicology and Therapeutics, University/BHF Centre for Cardiovascular Science, Edinburgh University, UK.
University of Liverpool · GBEdinburgh Royal Infirmary · GBCentre de Recherche sur l'Inflammation · FRGuy's and St Thomas' NHS Foundation Trust · GBQiagen (United States) · US

Funding

British Heart Foundation FS/11/52/29018Chief Scientist Office ETM/191Medical Research Council MR/K026666/1Medical Research Council MR/L006758/1
6 · The paper itself

Abstract

Our objective was to identify microRNA (miRNA) biomarkers of drug-induced liver and kidney injury by profiling the circulating miRNome in patients with acetaminophen overdose. Plasma miRNAs were quantified in age- and sex-matched overdose patients with (N = 27) and without (N = 27) organ injury (APAP-TOX and APAP-no TOX, respectively). Classifier miRNAs were tested in a separate cohort (N = 81). miRNA specificity was determined in non-acetaminophen liver injury and murine models. Sensitivity was tested by stratification of patients at hospital presentation (N = 67). From 1809 miRNAs, 75 were 3-fold or more increased and 46 were 3-fold or more decreased with APAP-TOX. A 16 miRNA classifier model accurately diagnosed APAP-TOX in the test cohort. In humans, the miRNAs with the largest increase (miR-122-5p, miR-885-5p, miR-151a-3p) and the highest rank in the classifier model (miR-382-5p) accurately reported non-acetaminophen liver injury and were unaffected by kidney injury. miR-122-5p was more sensitive than ALT for reporting liver injury at hospital presentation, especially combined with miR-483-3p. A miRNA panel was associated with human kidney dysfunction. In mice, miR-122-5p, miR-151a-3p and miR-382-5p specifically reported APAP toxicity - being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced kidney injury.

Indexed as

AcetaminophenAcute Kidney InjuryAlanine TransaminaseAnimalsBiomarkersChemical and Drug Induced Liver InjuryFemaleGene Expression ProfilingGene Expression RegulationHumansMaleMiceMicroRNAsAcetaminophenAlanine TransaminaseBiomarkersMicroRNAs

Identifiers

PMID26489516
PMCPMC4614545
OpenAlexW2179842400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.